Universite de Montreal
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Universite de Montreal
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.
With later-stage in-licensing assets becoming harder to find, Merck is seeking to work more often and in varied ways with academic and institutional researchers to advance its pipeline. Recent tech transfer deals include Cancer Research UK’s transactions with ProNAi and Artios.
Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.
A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Institute for Research in Immunology and Cancer (IRIC)